As a result of the absence of strains of Neisseria gonorrhoeae
resistant to the expanded spectrum of cephems, the National Committee for Clinical Laboratory Standards (NCCLS) (8
) has not defined the breakpoint MICs of expanded-spectrum cephems such as cefixime (CFM), cefpodoxime (CPD), cefepime (FEP), etc. A previous study reported the incidence of clinical failures in gonococcal urethritis treated with cefdinir (CDR) or aztreonam (ATM) (1
). For the N. gonorrhoeae
isolates from such clinical failure cases, high-level MICs of CDR, ATM, and other β-lactams were observed. In order to investigate the prevalence of these resistant isolates in Kitakyushu, Japan, we examined 54 N. gonorrhoeae
isolates from different cases occurring during 1999 for susceptibility to a variety of antimicrobial agents. Forty of 54 strains were isolated from male patients with gonococcal urethritis, while the remaining isolates were from female patients with gonococcal cervicitis. Identification of N. gonorrhoeae
and testing for production of β-lactamase were performed by ID-test-HN-20 Rapid (Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) using colonies cultured on Thayer-Martin Agar Base, Modified (Nissui Pharmaceutical Co.). The MICs of various antimicrobials were determined by the twofold serial agar dilution method on BBL GC Agar Base (Becton Dickinson and Co., Cockeysville, Md) with 1% BBL IsoVitalX enrichment (Becton Dickinson Europe, Meylan, France) according to the guidelines of the NCCLS (8
). The antimicrobial agents used in this study were purchased from or provided by the corresponding companies.
The MIC distribution of cefozopran (CZO) for N. gonorrhoeae isolates was divided into two groups. The MICs for the high-level resistance group (8 to 16 μg/ml) were more than 16 times greater than the MICs for the susceptible and low-level resistance groups (<0.5 μg/ml). The MICs of CZO were correlated with those of CDR, CPD, cefpirome (CPI), FEP, ATM, cefuroxime, cefotiam, ceftizoxime (ZOX), CFM, and cefcapene (CPN). The MICs of CZO correlated poorly with those of penicillin (PEN), cefmetazole, flomoxef, and cefodizime (CDZ) despite the fact that all 17 CZO-resistant isolates for these four agents belonged to the high-level MIC group. CFM, CDZ and ceftriaxone (CRO) exhibited lower MICs but the resistant isolates belonged to the group with reduced susceptibility to these three agents. These new resistant strains were clearly divided into two groups by the MIC distribution of CZO, with all of the CZO-resistant isolates exhibiting either resistance or a reduced susceptibility to all β-lactams tested. Clinical failures caused by these resistant isolates occurred in three patients treated with CDR or ATM (Table ). For these 17 isolates, high-level MICs for penicillins, narrow- and expanded-spectrum cephalosporins, cephamycins, the majority of broad-spectrum oral cephalosporins, and aztreonam were observed, together with a reduced susceptibility to most broad-spectrum parenteral cephalosporins. In the measurement of MIC and the disk diffusion test, these resistant isolates can be identified easily with CZO. CZO has been rarely used in gonococcal infection, but we consider that it may well be profitable to use CZO to define this resistant organism. We therefore called these isolates CZO-resistant N. gonorrhoeae (CZRNG). These strains did not produce β-lactamase. CZRNG accounted for 32% (17/54) of all isolates tested. The MICs of CDZ, CRO, and spectinomycin (SPT) showed that the isolates were susceptible, while CFM, cefotaxime (CTX), and ZOX retained good activity. To other β-lactams, the isolates were resistant or had a reduced susceptibility. All of the 17 CZRNG isolates were resistant to ciprofloxacin (CIP), with MICs of this drug ranging between 0.125 and 64 μg/ml. Six of 17 isolates exhibited high resistance to ciprofloxacin (MICs > 2 μg/ml). All 17 isolates were resistant to tetracycline (MIC, 1 to 4 μg/ml). The MICs of minocycline (MIN) for 15 of the 17 isolates were greater than 0.5 μg/ml. The MIC of erythromycin for one isolate was 0.125 μg/ml, while MICs for the other isolates had values of 4 to 16 μg/ml. Thus, 17 CZRNG isolates were multiresistant strains.
Clinical data of 17 cefozopran-resistant N. gonorrhoeae isolatesa
We therefore performed restriction fragment length polymorphism (RFLP) analysis as described by Struelens et al. (10
) using a CHEFF Mapper pulsed-field gel electrophoresis system (Nippon Bio-Rad Laboratories, Tokyo, Japan). Figure and Table present the results of the macrorestriction genomic DNA analysis by Spe
I carried out with 17 CZRNG strains. The 17 strains were isolated over a period of 8 months (May to December) from 17 cases at nine hospitals that were scattered within a radius of 40 km. Although the 17 CZRNG strains were isolated from multiple patients, RFLP analysis clearly divided the isolates into only two groups. The RFLP patterns by Spe
I of the two groups differed by only one band. Molecular analysis software (Molecular Analyst Fingerprinting Plus; Nippon Bio-Rad Laboratories) indicated that the two groups were greater than 90% similar. The 17 CZRNG isolates underwent further RFLP typing by Nhe
), which produced identical RFLP patterns for all of the 17 CZRNG isolates. These results indicate that the outbreak of CZRNG isolates in Kitakyushu, Japan, occurred as a result of clonal spread.
FIG. 1 The SpeI restriction patterns of chromosomal DNAs from 17 cefozopran-resistant Neisseria gonorrhoeae isolates. MW, λ DNA ladders; A, SNG27; B, SNG28; C, SNG32; D, SNG33; E, SNG46; F, SNG50; G, SNG52; H, SNG53; I, SNG54; J, SNG57; K, SNG65; L, (more ...)
DNA typing patterns and antimicrobial susceptibilities of 17 cefozopran resistant N. gonorrhoeae isolates
The CZRNG strain was first isolated at a hospital in Kitakyushu, Japan, in May, 1999. After that, the frequency of patients suffering from CZRNG rapidly increased such that the ratio of CZRNG among N. gonorrhoeae
isolates reached 45.5% (5/11) during the month of December 1999. To our surprise, the genomic RFLP analysis revealed that the outbreak of CZRNG isolates occurred due to clonal spread. In Japan, most patients suffering from N. gonorrhoeae
are treated with oral antimicrobials such as penicillins, broad-spectrum cephems, fluoroquinolones, and tetracyclines. Therefore, the emergence of CZRNG isolates resistant to cephems, fluoroquinolones, and tetracyclines is of serious concern. In the cases of gonococcal infection caused by CZRNG, the administration of 1 g of CRO, 1 g of CDZ, or 2 g of SPT was effective (Table ). In Japan, CRO has not been recognized for use in gonococcal infections, and we have therefore treated patients with gonococcal infections with CDZ or SPT. Although SPT-resistant isolates were not isolated in this study, there have been reports of SPT-resistant N. gonorrhoeae
isolates in other areas (6
). We therefore recommend that CDZ be used as the first-line treatment for gonococcal infection.
It has been reported that the mechanisms of low-level resistance to β-lactams, including cephems, involved the mutation of the porin encoded at the penB
) and the decreased affinity of β-lactams to PBP-2 (2
). Recently, we have discovered that many codons of the PBP-2 gene (penA
) of the CZRNG isolates were different from those of the other susceptible isolates (data not shown). This area is under further investigation since this may be a potential resistance mechanism of CZRNG.